Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700534 | 1.00 | MAPT (0.61) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| Water SCHEMBL13834852 | 0.98 | MAPT (0.59) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL29405531 | 0.84 | MAPT (0.73) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL335038 | 0.84 | MAPT (0.73) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL5512898 | 0.84 | MAPT (0.58) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL3189109 | 0.83 | MAPT (0.72) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL29378830 | 0.83 | MAPT (0.72) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL6331318 | 0.82 | MAPT (0.49) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL21822828 | 0.82 | MAPT (0.49) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL31166967 | 0.82 | MAPT (0.49) | MAPTKDM4EHSD17B10MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035383-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION THERAPEUTICS AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-20250223462-A1 | ELECTRONIC COMPONENT | NIHON PARKERIZING CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| EP-3642210-B1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION THERAPEUTICS AS (DK) | 2024-11-13 | — | — | EP | disclosed |
| US-20240300962-A1 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | PROSETTA BIOSCIENCES INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-12084457-B2 | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | UNION therapeutics A/S (DK) | 2024-09-10 | — | — | US | disclosed |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | PROSETTA BIOSCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | PROSETTA BIOSCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2023195439-A1 | ELECTRONIC COMPONENT | 日本パーカライジング株式会社 | 2023-10-12 | — | — | WO | disclosed |
| EP-3390407-B1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION THERAPEUTICS AS (DK) | 2023-10-11 | — | — | EP | disclosed |
| EP-4149471-A1 | ISOQUINOLINE DERIVATIVES, METHODS OF SYNTHESIS AND USES THEREOF | Prosetta Biosciences, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2008122620-A1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERISATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-10-16 | — | — | WO | disclosed |
| EP-1373257-B9 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006051-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1373257-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-28 | — | — | EP | disclosed |
| US-6949544-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1373257-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-08 | — | — | US | disclosed |
| WO-2002079197-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | MAPT 4437/4885KDM4E 1489/4885HSD17B10 280/4885 |
| US-12024521-B2 | Isoquinoline derivatives, methods of synthesis and uses thereof | POLRMT, MAVS, SYNCRIP | MAPT 200/4885KDM4E 2540/4885HSD17B10 2988/4885 |
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CDK2, LCK, CDK5 | MAPT 1864/4885KDM4E 1096/4885HSD17B10 4252/4885 |
| US-20240300962-A1 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | POLRMT, MAVS, SYNCRIP | MAPT 200/4885KDM4E 2540/4885HSD17B10 2988/4885 |
| US-12084457-B2 | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | PDE4B, PDE4A, PDE4C | MAPT 4370/4885KDM4E 311/4885HSD17B10 892/4885 |
| US-20260035383-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | NOX4, PDE3B, CBR1 | MAPT 4848/4885KDM4E 876/4885HSD17B10 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.